EMA authorises “Restore”, Oryzon Genomics’ Phase Ib clinical trial on iadademstat in sickle cell anaemia (SCA)
Alphavalue / Divacons | The Spanish biopharmaceutical company has received authorisation from the European Medicines Agency (EMA) to initiate a Phase Ib clinical trial of iadademstat in sickle cell anaemia (SCA). This is the first clinical trial to investigate iadademstat in a non-malignant haematological indication. The study, called “Restore”, will be conducted at several centres in Spain and will recruit 40 adult patients. The main objectives of the trial are…
